<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Current approach of juvenile nasopharyngeal angiofibroma: a case series.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Current approach of juvenile nasopharyngeal angiofibroma: a case series." class="clickable-image" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593122/bin/RJME-63-1-105-fig6.jpg"/> </div> <div class="text-side"> <h1>Current approach of juvenile nasopharyngeal angiofibroma: a case series.</h1> <p>Immunohistochemical aspects of nasopharyngeal angiofibroma: (A) Tumoral vessels of varying caliber and shape, bounded by an uninterrupted row of endothelial cells; (B) Smooth muscle cells irregularly disposed within the tumor vessel wall; (C) Moderate inflammatory infiltrate present within the tumor stroma; (D) Tumor stroma infiltrated by numerous T-lymphocytes; (E) Tumor stroma with a low B-lymphocytes content; (F) Tumor stroma with a low macrophages count. Anti-CD34 antibody immunomarking: (A) ×200. Anti-α-SMA antibody immunomarking: (B) ×100. Anti-CD45RO antibody immunomarking: (C) ×200. Anti-CD3 antibody immunomarking: (D) ×200. Anti-CD20 antibody immuno-marking: (E) ×200. Anti-CD68 antibody immunomarking: (F) ×200. α-SMA: Alpha-smooth muscle actin; CD: Cluster of differentiation</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36074673/" target="_blank">36074673</a></p><p>Type: Benign, Category: Fibrohistiocytic</p>
</div> </div></div></body></html>